ArticleAIDS (London, England)2025
Machine learning algorithms to predict the risk of hyperlipidemia in people with HIV after starting HAART for 6 months.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in HIV research: a structured review and task-oriented clinical framework.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to use machine learning models to predict the risk of hyperlipidemia in people with HIV (PWH) for 6 months after starting HAART, to improve early intervention efforts and prevent further progression to cardiovascular and cerebrovascular diseases.
methodsThis study enrolled HAART-naive individuals who visited the clinic at Beijing Ditan Hospital between January 2015 and January 2023. All clinical features were extracted from the electronic medical records. A classification prediction model was established based on various machine learning algorithms, including Random Forest (RF), Extreme Gradient Boosting (XGBoost), and Light Gradient Boosting Machine (LightGBM), to predict the risk of hyperlipidemia based on accuracy, positive-predictive value, negative-predictive value, sensitivity, and specificity. Receiver operating characteristic (ROC) curve, precision-recall curve, and decision curve analyses were used to visually evaluate the model.
resultsA total of 2479 participants (median age, 33 years) were included, of which 2380 (96.01%) were male and 99 (3.99%) were female. The LightGBM model performed the best among all the models in both the training and testing sets. This model performed well in the decision curve analysis (DCA), and baseline high-density lipoprotein cholesterol (HDL-C), baseline triglycerides, baseline viral load, age, albumin, monocyte count, baseline CD4 + cell count, uric acid level, lymphocyte count, and sex were the top 10 predictive risk factors for hyperlipidemia in PWH who started HAART treatment for 6 months, based on SHAP analysis.
conclusionThis study demonstrated that the LightGBM model can effectively predict the risk of hyperlipidemia in PWH after starting HAART treatment for 6 months and reminded physicians closely to monitor serum lipid levels or the timely addition of lipid-lowering drugs, which helped prevent the occurrence of cardiovascular diseases among PWH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.